Pfizer Brings Back QUEST® PLUS Gel dewormer

Newsdate: Fri, 21 Oct 2011 - 07:30 am
Location: MADISON, New Jersey

Pfizer Animal Health is reintroducing QUEST® PLUS (moxidectin/praziquantel) Gel dewormer. QUEST PLUS has been on back order and unavailable to horse owners and veterinarians for quite some time. Now the product is back on the market just in time for fall deworming to help protect horses against the tapeworm threat, as well as other serious internal parasites.

QUEST® PLUS (moxidectin/praziquantel), is a long-lasting, effective dewormer that helps protect against a broad range of parasites including large and small strongyles, roundworms, pinworms, hairworms, stomach worms, bots, and encysted small strongyles (bloodworms).

QUEST PLUS contains the same active ingredients as QUEST® (moxidectin) gel, but with the additional benefit of praziquantel for treatment and control of tapeworms (A.perfoliatum). Both dewormers provide up to 84 days of protection from strongyle egg reinfection and 14 days without inflammation in just one dose[i].

“We are thrilled to have QUEST PLUS back on the shelves and available for our customers,” said Kristin Ruff, Director at Pfizer Animal Health. “Pfizer Animal Health offers the most comprehensive deworming product portfolio. Now with QUEST PLUS back in the mix, the portfolio is truly complete.” 

Tapeworms can pose a medical threat to horses across the United States. A ground breaking study in equine parasitology, done in 2003 by Dr. Craig Reinemeyer of East Tennessee Clinical Research, uncovered a high prevalence of equine tapeworms (A.perfoliatum) throughout the United States. Updated data from Pfizer Animal Health showed tapeworm prevalence on west coast farms as 17.3% in California, 36.5% in Oregon and 25.3% in Washington1.

Horse owners can ensure their horses are protected from tapeworms by incorporating a praziquantel dewormer, such as QUEST PLUS, into their deworming program. This class of anthelmintic has been proven effective against tapeworm infections and is commercially available. Be sure to consult a veterinarian before making any changes to your deworming program.

QUEST and QUEST PLUS are approved for use in all breeds of horses and ponies. QUEST is safe in breeding mares and stallions, and foals six months of age and older. Reproductive studies evaluating safety of use of QUEST PLUS in reproductive mares and breeding stallions have not been conducted. For more information on QUEST and QUEST PLUS, visit www.Questhorse.com.

Important Safety Information

Extreme caution should be used when administering QUEST and QUEST PLUS to foals, young and miniature horses, as over dosage may result in serious adverse reactions. Do not use in sick, debilitated or underweight animals. These products should not be used in other animal species, as severe adverse reactions, including fatalities in dogs, may result. For more information on QUEST or QUEST PLUS visit www.QUESThorse.com.

About Pfizer Animal Health

Pfizer Animal Health, a business unit of Pfizer Inc, is a world leader in the discovery, development and manufacture of innovative animal health vaccines, medicines, and diagnostic products.  Pfizer Animal Health invests more in research and development than any other animal health company.  We work to assure a safe, sustainable global food supply from healthy beef and dairy cattle, swine, poultry and fish while helping dogs, cats and horses live healthier longer lives.  We strive to be the animal health company that provides full healthcare solutions to veterinarians, livestock producers, and pet owners.  To learn more, visit www.us.animalhealth.pfizer.com.

All brands are the property of their respective owners. ©2011 Pfizer Inc. All rights reserved

References:

1 C.R. Reinemeyer, A.W. Farley, S.A. Kania, B.W. Rohrbach and R.H. Dressler, 48th Annual Meeting of the American Association of Veterinary Parasitologists, Denver, CO, July 2003. Updated West Coast Farm prevelance of tapeworm infection data. Data on file. Pfizer Inc. 2009.

2 Steinbach, et al, Strongyle infection: Consequences of Larvicidal Treatment of Horses with  Fenbendazole and Moxidectin.  Vet Parasitology 139 (2006) 115-131.

3 Betancourt,A., E. Lyons, and D. Horohov. The Effect of Anthelmintics on Proinflammatory Cytokine Responses in Treated Horses. 2010 Conference of Research Workers in Animal Diseases. December 5-7 2010.

About the Author

Flossie Sellers

Author picture

As an animal lover since childhood, Flossie was delighted when Mark, the CEO and developer of EquiMed asked her to join his team of contributors.

She enrolled in My Horse University at Michigan State and completed a number of courses in everything related to horse health, nutrition, diseases and conditions, medications, hoof and dental care, barn safety, and first aid.

Staying up-to-date on the latest developments in horse care and equine health is now a habit, and she enjoys sharing a wealth of information with horse owners everywhere.

Subscribe